The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
International medical graduates (IMG) representation at international oncology conference meetings.
 
Arya Mariam Roy
No Relationships to Disclose
 
Ziad Bakouny
Honoraria - UpToDate
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
(OPTIONAL) Uncompensated Relationships - ASCO IMG Community of Practice; IMG Oncologists (NGO)
 
Nazli Dizman
Stock and Other Ownership Interests - Several pharmaceutical companies (I)
Consulting or Advisory Role - Vivreon Biosciences
 
Zeynep Irem Ozay
No Relationships to Disclose
 
Bhavesh Mohan Lal
No Relationships to Disclose
 
Rashad Nawfal
No Relationships to Disclose
 
Marc Eid
No Relationships to Disclose
 
Razane El Hajj Chehade
No Relationships to Disclose
 
Marc Machaalani
No Relationships to Disclose
 
Ayesha Butt
No Relationships to Disclose
 
Charu Aggarwal
Consulting or Advisory Role - Abbvie; Arcus Biosciences; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Janssen; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; Novocure; Pfizer; Sanofi/Regeneron; Takeda
Speakers' Bureau - AstraZeneca (I); Roche/Genentech (I)
Research Funding - AstraZeneca/MedImmune (Inst); Candel Therapeutics (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Loxo@Lilly (Inst); Merck Sharp & Dohme (Inst)
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Mariana Chavez-MacGregor
Employment - MD Anderson Physician’s Network
Consulting or Advisory Role - Abbott Laboratories; Adium Pharma; AstraZeneca/Daiichi Sankyo; Exact Sciences; Exact Sciences; Lilly; Merck; Pfizer; Roche/Genentech
Research Funding - Genentech/Roche (Inst); Lilly; Novartis (Inst); Pfizer (Inst)
Expert Testimony - Lilly
Travel, Accommodations, Expenses - AstraZeneca; Exact Sciences; Zodiac Pharma
(OPTIONAL) Uncompensated Relationships - Legacy Healthcare Services; The Hope Foundation
 
Gilberto Lopes
Stock and Other Ownership Interests - Biomab; CDR-Life; Lucence Diagnostics; Morphometrix; Xilis
Honoraria - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Janssen; Merck
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); E.R. Squibb Sons, LLC; EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst); Xilis
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Celgene; E.R. Squibb Sons, LLC; Ipsen; Janssen; Merck; Pfizer; Pharmacyclics; Seagen; Seagen
Other Relationship - Mirati Therapeutics
 
Ariela Lucy Marshall
Stock and Other Ownership Interests - Teladoc
 
Martina Cathryn Murphy
Honoraria - IntegrityCE
 
Taofeek K. Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES; Coherus Biosciences; GenCart; Taobob LLC
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Coherus Biosciences; Daichi; Eisai; Eisai; EMD Serono; Exelixis; G1 Therapeutics; Heat Biologics; Ipsen; Janssen; Jazz Pharmaceuticals; Lilly; MedImmune; Merck; Meryx Pharmaceuticals; Novartis; PharmaMar; Puma Biotechnology; Roche/Genentech; Takeda; Triptych Health Partners; Xcovery
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals; G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Loxo/Lilly (Inst); Merck (Inst); Meryx Pharmaceuticals (Inst); Novartis (Inst); Oncorus (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen
Other Relationship - EMD Serono; Novartis; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Alfred Ian Lee
No Relationships to Disclose
 
Toni K. CHOUEIRI
Stock and Other Ownership Interests - Curesponse; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel